Novartis

Novartis launched the first fixed-dose Artemisinin-based Combination Therapy (ACT) for malaria over 25 years ago and continues to discover and develop next-generation antimalarial medicines, including treatments designed to work against drug-resistant malaria and to simplify treatment for children and adults.¹ Its U.S. malaria R&D footprint includes East Hanover New Jersey, Cambridge, Massachusetts, and sites in Emeryville and San Diego, California.¹ Novartis's malaria pipeline spans the discovery and development stages, from early compounds like INE963 and IWY357, to those in later stage clinical development such as cipargamin (Phase II/III) and ganaplacide, which in combination with lumefantrine is in pre-registration following completion of a positive Phase III clinical study.¹ Novartis’s efforts are part of a broader strategy to address drug-resistant malaria and improve treatment for infants and adults with uncomplicated or severe disease.¹